Topic Review

Journal of Neuro-Oncology

, Volume 108, Issue 1, pp 11-27

First online:

Open Access This content is freely available online to anyone, anywhere at any time.

Recent advances in the molecular understanding of glioblastoma

  • Fonnet E. BleekerAffiliated withDepartment of Neurosurgery, H2 247, Neurosurgical Center Amsterdam, Location AMC Email author 
  • , Remco J. MolenaarAffiliated withDepartment of Cell Biology and Histology, Academic Medical Center, University of Amsterdam
  • , Sieger LeenstraAffiliated withDepartment of Neurosurgery, Erasmus Medical CenterDepartment of Neurosurgery, St. Elisabeth Ziekenhuis


Glioblastoma is the most common and most aggressive primary brain tumor. Despite maximum treatment, patients only have a median survival time of 15 months, because of the tumor’s resistance to current therapeutic approaches. Thus far, methylation of the O 6-methylguanine-DNA methyltransferase (MGMT) promoter has been the only confirmed molecular predictive factor in glioblastoma. Novel “genome-wide” techniques have identified additional important molecular alterations as mutations in isocitrate dehydrogenase 1 (IDH1) and its prognostic importance. This review summarizes findings and techniques of genetic, epigenetic, transcriptional, and proteomic studies of glioblastoma. It provides the clinician with an up-to-date overview of current identified molecular alterations that should ultimately lead to new therapeutic targets and more individualized treatment approaches in glioblastoma.


Glioblastoma Molecular (Epi)genetic Transcriptional Proteomic